Skip to content

Study · In vitro (cells) · 1986

1 result

Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones.

Sztein MB, Serrate SA, Goldstein AL

Proceedings of the National Academy of Sciences of the United States of America1 Aug 1986Cited by 54 (Europe PMC)

PMID3090550 (opens in a new tab)PMCIDPMC386448 (opens in a new tab)DOI10.1073/pnas.83.16.6107 (opens in a new tab)PepBankPUB-03090550
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In PHA-stimulated normal human lymphocytes, synthetic thymosin alpha‑1 increased IL-2 receptor expression.

    In plain wordsIn human immune cells in the lab, thymosin alpha‑1 raised the amount of IL-2 receptor on the cell surface.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseIL-2 receptor expression on PHA-stimulated lymphocytes
    Study

    humann: not reported in source

    PHA-stimulated normal human lymphocytes
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Thymosin alpha 1, a synthetic polypeptide originally isolated in its native form from TF5, was also able to increase IL-2R expression in response to PHA, suggesting that it is the active species in TF5.
    1 context sentence
    Summary · context
    Since thymosin fraction 5 (TF5), a thymic hormone preparation, enhances lymphoproliferative responses of human cells, we examined the effects of TF5 on the expression of IL-2R on mitogen-stimulated human lymphocytes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.